July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Supplementation with alpha lipoic acid to treat geographic atrophy from AMD
Author Affiliations & Notes
  • Benjamin J Kim
    Ophthalmology, Scheie Eye Institute / UPenn, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Benjamin Kim, Allergan (C), Synergy Research Inc. (C)
  • Footnotes
    Support  BrightFocus Foundation, Cures Within Reach, Pennsylvania Lions Sight Conservation and Eye Research Foundation
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4216. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Benjamin J Kim; Supplementation with alpha lipoic acid to treat geographic atrophy from AMD. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4216.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : This presentation will provide information on a phase II pilot, multicenter, placebo-controlled clinical trial (NCT02613572) evaluating the re-purposing of alpha lipoic acid as a treatment for the geographic atrophy of age-related macular degeneration (AMD). Background will be provided on alpha lipoic acid, a nutraceutical that is a potent antioxidant and iron-chelator. Animal model data relevant to AMD will be discussed. The trial design will be covered in detail. There are no patient treatment recommendations in this presentation.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.